We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HAEMONETICS

Haemonetics Corporation’s comprehensive portfolio of devices, information management, and consulting services offers ... read more Featured Products: More products

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Haemonetics Displays Small, Cartridge-Based TEG 6s Hemostasis Analyzer at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 29 Sep 2021

Haemonetics Corporation (Boston, MA, USA) displayed its small, cartridge-based TEG 6s hemostasis analyzer at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s premier gathering of clinical lab professionals from around the world. More...

Haemonetics provides blood management solutions to help improve care & reduce costs. The company’s TEG 6s system addresses the limitations of traditional testing by delivering fast, comprehensive, & functional assessment of coagulation. The analyzer’s easy-to-use test cartridge delivers a rapid, comprehensive picture of patient hemostasis giving invaluable insight. With a small footprint, robust quality control processes, vibration resistance, and simple, automated cartridge the TEG 6s can be readily deployed in varied settings.

Alongside the TEG 6s hemostasis analyzer, Haemonetics also demonstrated the TEG Manager software that allows secure, real time remote access to patient results, analyzer/user admin & LIS/POC system connectivity. The TEG Manager software system delivers convenient, secure TEG analyzer results viewing and system administration. It provides for robust TEG analyzer data warehousing, real-time, on-demand remote patient results viewing, clinical report generation, LIS connectivity, and user/device management/reporting. The Interpretation Guidance module allows clinicians the option to customize clinical alert messages according to your institution’s guidelines. It displays active and historical TEG results wherever/whenever within the hospital network. It also provides administrative functions including dashboard views of the status of all TEG analyzers throughout the hospital, manage users/access, and a robust suite of operational and audit reporting.

Related Links:
Haemonetics Corporation 


Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.